Coronavirus disease 2019 vaccination in solid organ transplant recipients
10.3760/cma.j.cn114015-20210624-00707
- VernacularTitle:实体器官移植受者的新型冠状病毒肺炎疫苗接种
- Author:
Yueyuan WANG
1
;
Yanglin ZHOU
1
;
Liu YANG
1
;
Mengqiu GOU
1
;
Yuan BIAN
1
Author Information
1. 四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部·个体化药物治疗四川省重点实验室，成都 610072
- Publication Type:Journal Article
- Keywords:
Organ transplantation;
SARS-CoV-2;
Vaccination;
COVID-19 vaccines
- From:
Adverse Drug Reactions Journal
2021;23(7):348-351
- CountryChina
- Language:Chinese
-
Abstract:
Solid organ transplant (SOT) recipients are a high-risk population for coronavirus disease 2019 (COVID-19), and the safety and efficacy of COVID-19 vaccines in this population is of great concern. At present, the published studies on COVID-19 vaccines for SOT recipients are mainly about mRNA vaccines and there are a few cases reports on recombinant adenovirus vector-based vaccines. These results show that the COVID-19 vaccines are safe for the SOT recipients, but the immune response rates are lower and the incidence of vaccine breakthrough infections is higher than that in the general population. Based on the results of the current studies, SOT recipients can start to be vaccinated with COVID-19 vaccines 1 to 3 months after organ transplantation. Prevention of COVID-19 after vaccination is still necessary to avoid vaccine breakthrough infections.
